Yesterday, IndieBio presented New York Batch 5 for an online Demo Day, an event that highlights new companies in the IndieBio fold. Unique to this year’s Demo Day was the location of the event: IndieBio’s new 25,000 sq. ft. office, lab, and event space at 7 Penn Plaza in New York City.
IndieBio’s managing director Stephen Chambers led Demo Day, introducing the 10 companies in New York Batch 5, and SOSV managing general partner Sean O’Sullivan offered closing remarks on the companies’ potential impact on climate change, human health, and beyond. The founders of each company presented on stage about their plans to address existing challenges within the food industry, biomaterials, femtech, industrial biotech, therapeutics, and drug discovery. Learn more about each of the New York Batch 5 companies below—and be sure to check out their Demo Day presentations, too!
BioFluff is developing a biodegradable, cost-competitive, and high-quality alternative to animal and synthetic furs for the luxury clothing market. As the world’s first completely plant-based fur, BioFluff’s product is free from plastic and GMOs and is sourced from organic renewable fiber plants—meaning no pesticides, herbicides, insecticides, petrochemicals or unsustainable raw-oil derivatives in the manufacturing process.
FluoSphera is devising the first-ever liquid microphysiological systems (MPS) to revolutionize drug discovery, increase the success rate of clinical trials, and propose superior alternatives to animal experimentation. FluoSphera’s MPS mimics the communication between multiple human organs in vitro to more accurately predict the effects of candidate drugs—even before they reach the first patient—and pinpoint the most promising drugs.
Edge is solving one of the main roadblocks to the cultivated meat industry: finding a growth factor without extensive downstream processing. To do this, the company has created a novel bioprocess using animal cell factories that self-supply authentic growth factors. Edge’s method doesn’t require the isolation and purification steps of recombinant protein production (common in fermentation and molecular farming), significantly cutting costs while providing a constant supply of growth factors and reducing contamination risk.
Forte Protein is building a technology platform to sustainably produce bio-identical animal proteins such as ovalbumin and lactoferrin within plants like lettuce or kale. These proteins can be ingredients for non-GMO, vegan, kosher, and gluten-free supplements, gels, dairy and meat alternatives, and energy drinks. The company can also repurpose their plant waste as feedstock, fertilizer, biofuel, extracts, and other plant compounds to bring in an additional revenue stream.
Atlantic Fish Co is developing cultivated seafood that is both delicious and sustainable. The company harvests cells from fish, feeds nutrients in a bioreactor, and uses scaffolding to yield the texture of a whole fish filet. The resulting seafood is real fish-cell-based cuisine without the environmental and health consequences of conventional fish farming.
Vader Nanotechnology designs new organisms and enzymes that break down plastic and chemical pollutants. Using automation, image processing and computer vision, and analytical chemistry, the company chooses organisms that can grow on plastics and chemicals that resist natural degradation and optimizes these organisms’ performance.
Vitarka Therapeutics has developed EndoPore, a drug-delivery solution that uses synthetic biology to create pore forming proteins (PFPs) for targeted, cytosolic delivery of RNA therapeutics. Vitarka Therapeutics is exploiting PFP’s naturally-evolved mechanism of endosomal escape and its mechanism of stabilizing RNA.
Pneuma is creating a living, breathing textile, OXYA, seeded with microalgae that consumes carbon dioxide and produces oxygen. By engineering living materials that can photosynthesize and make oxygen, Pneuma hopes to promote healthier, more sustainable apparel and home-ware industries.
Bioeutectics is making green solvents mainstream with its non-toxic, biodegradable, and sustainable solvents. Using a combination of eutectic technology and green chemistry, Bioeutectics is customizing products for industries spanning food, pharma, and personal care.
AIMA is innovating period pain management with CBD-infused products—the first to be tested being OVY. This vaginal suppository acts as a safe and effective pain management solution for menstruators with dosages based on personalized pain response.